Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. - Wikidata - wikimedia - TriplyDB

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q36796803

about

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background Bile acid receptors and nonalcoholic fatty liver disease Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer Gut Microbiota and Host Reaction in Liver Diseases Bile acid signaling in metabolic disease and drug therapy Developmental origins of NAFLD: a womb with a clue.Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease.A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo.Genome-wide binding and transcriptome analysis of human farnesoid X receptor in primary human hepatocytes.Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies Ly6C- Monocytes Regulate Parasite-Induced Liver Inflammation by Inducing the Differentiation of Pathogenic Ly6C+ Monocytes into Macrophages Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis.Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle.Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease.Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.TGR5 signaling reduces neuroinflammation during hepatic encephalopathy.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Bile acid receptors in non-alcoholic fatty liver disease.Are GPCRs still a source of new targets?Pharmacological agents for NASH.The bile acid TGR5 membrane receptor: from basic research to clinical application.TGR5 in inflammation and cardiovascular disease.Genetics in PSC: what do the "risk genes" teach us?Evolving therapies for non-alcoholic steatohepatitis.Review article: new treatments in non-alcoholic fatty liver disease.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4-/- Mice.Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis.

P2860

Q26744380-64BD9A44-8B92-476D-85E5-9CD6910F3589 Q26775814-00E653FC-B887-4231-A08D-1BBBA79708E6 Q26800206-411E41B7-66AF-4C6A-BFAE-A98AD6D44068 Q28083295-3C27C577-9190-41C4-B175-9B304B5B3BEB Q28244875-84CFA5F5-B341-485B-9C37-9DE1B6824752 Q30241940-C2AFC451-63A0-44D8-A50D-0E988FC8976A Q33805839-D75643D2-C202-43FE-98A7-89872952E16E Q33812525-762BA4FD-866F-4BE5-8CF0-D21401D4A748 Q34149571-50B6091C-408F-4650-84CB-CC1412253205 Q34215923-54F7B38A-ECAE-49FE-9DF2-349948AB7453 Q34303001-2627FD3F-FB77-4D50-8B4D-572F4945FACF Q34366966-08E716B8-03EC-4046-9F24-A22F2C65ECE3 Q34401755-EA196391-FDD3-4E70-A7CC-46AC8AA5A942 Q34425909-CA74D68D-38F2-4F63-81B4-5FDD660D4647 Q34540703-EA1C5E97-E710-4769-B993-28E08070FA23 Q34647400-90931849-9AE3-4D93-BBF5-F7668275C24B Q34657286-A7D2CA82-BCEA-42B0-8644-7E05552C73CD Q35644935-A44737B9-2C28-4CB4-A27B-15ACD888ADD5 Q35849928-81E67254-8A77-4882-B56C-220827452EF8 Q35914082-7BDCF201-A239-427D-AE8C-0571FE6A9B0E Q36084783-AA2F0E46-8C38-423A-844B-2BFB1F32E8D9 Q36089858-AB52FB1B-4E37-408E-9E29-7648DEF6F8FC Q36368928-CFD8FA13-915E-4081-8645-0FE4D399F9E0 Q36464051-86997137-4C21-4E3C-B8F7-4D8950952DCB Q37272976-E2EE89A3-9C17-498A-9AAE-9EE50050127E Q37538343-DFB8F884-ECBF-4764-A5D8-A13FD122B3FA Q37586952-8624F379-25E8-4E02-B26E-BA5C5928A617 Q38129012-6BCA159B-62C3-4E7A-BFF1-E71978D01657 Q38152646-E3F3DBAA-9552-4B8B-9CBF-421AF2F21A75 Q38177434-3F9E8ECF-9EED-400E-AA35-3110D8EBAA1C Q38197305-04313651-DC66-492D-82A4-0E4ED2232494 Q38204911-DDCA1F7A-9E62-496D-8CFE-3DBB05701DA2 Q38207111-7AFCBD36-4ACD-41E3-B641-65C8BBB072A7 Q38662765-AD1924EE-5537-4A4F-BB09-1AFE30AACB5A Q38752520-2FFA7B04-35AB-4FD3-9927-4A1B9327DEC2 Q39262148-04C0E235-9C21-4AB9-80AB-320F3A009719 Q41331841-6AF96AB5-28ED-4611-84C2-6F7D9336D207 Q41550270-E459FF27-716B-427E-A193-C172C423E120 Q41552497-4B622CB4-FBFF-4D89-B22E-C2F87B8559AF Q41649308-342368B8-7BE5-4619-86E5-F2E3A9F2BAF9

P2860

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

http://www.wikidata.org/entity/Q36796803

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Bile acid receptor activation ...... alcoholic fatty liver disease.

@en

type

label

Bile acid receptor activation ...... alcoholic fatty liver disease.

@en

prefLabel

Bile acid receptor activation ...... alcoholic fatty liver disease.

@en

P1433

Q36796803-1AF9E2D6-3864-44E8-B17E-141A87A81A23

P1476

Q36796803-D6B3D5F7-A9BB-4ADC-941B-B1E9F11B3340

P2093

Q36796803-0C26A38A-F14E-4590-8B68-E4555268DBE0

Q36796803-26C22BCF-168B-4FFA-A60A-B8ABC03C186E

Q36796803-33A7A151-1F0D-4B8D-BE35-F963870E549B

Q36796803-3D19F1F4-A675-4A39-A932-69F2847E707D

Q36796803-87CAF839-6969-49AB-8FAD-DF4CD5DE0042

Q36796803-AD25EF2B-E31C-4DD0-8CDF-7244DB41D380

Q36796803-E1F1ADF0-C7BE-4F8E-A3C4-7A671E3E2AD6

Q36796803-F315CD37-87B5-4FCB-823E-A3401CC2AD6D

Q36796803-F4F05422-1FBF-4364-A49F-24EA385ED300

P2860

Q36796803-0292ACD1-B6AA-4FC4-A6C9-1725D7B45209

Q36796803-0B275F30-36E6-4807-99DF-3C815A37554E

Q36796803-11842355-6F83-4E6B-A885-ECD5BCA704BD

Q36796803-1503E423-36BF-4C5C-A3D8-77029ADFCB40

Q36796803-29199C1D-6754-45C3-BBDB-A492211C9EFA

Q36796803-355B2897-6C34-4AB7-85E6-1CF2A03C79E0

Q36796803-3BFCAEDE-12C3-46D0-B54F-B186CD565FBB

Q36796803-3C100A22-FA21-4F7C-A843-21B023F7A1C2

Q36796803-3FA512CB-8133-434E-99EE-5ABBF5089DA6

Q36796803-3FB1675A-22E4-49F7-8986-0E71A5732FEF

P304

Q36796803-EA37ACA6-B69C-4718-BC06-4DE3901179A1

P31

Q36796803-7488E32C-E697-4B16-BA51-FE65C7A61BD2

P356

Q36796803-753F0DE4-5CEB-4B88-A324-4C8F63040BD7

P407

Q36796803-A91D9583-004C-4DB7-B5C5-77CDFC268F73

P433

Q36796803-AAEF4AAA-7298-4551-9311-FC3216A01493

P478

Q36796803-DEE5D905-A72F-49DF-8855-5438B5737B75

P50

Q36796803-67978264-9510-4781-9125-B7A2843A4908

Q36796803-BA478848-9E10-4857-81F9-E9E6478919C0

P577

Q36796803-F1F98E50-8E3C-402B-8CCC-FB45FAF37BCE

P5875

Q36796803-C310EC1F-FEFA-4D84-B72B-88B1BC1C7210

P698

Q36796803-EEA1696A-B22A-4ADA-A9A8-36D63CB9DA5C

P932

Q36796803-A75A1454-126E-478B-89DF-583003663497

P356

JBC.M112.446575

P1433

Journal of Biological Chemistry

P1476

Bile acid receptor activation ...... nalcoholic fatty liver disease

@en

P2093

Hugo R Rosen

http://www.w3.org/2001/XMLSchema#string

Karim El Kasmi

http://www.w3.org/2001/XMLSchema#string

Lin Ling Cheng

http://www.w3.org/2001/XMLSchema#string

Luciano Adorini

http://www.w3.org/2001/XMLSchema#string

Mark Pruzanski

http://www.w3.org/2001/XMLSchema#string

Maxwell Smith

http://www.w3.org/2001/XMLSchema#string

Rachel H McMahan

http://www.w3.org/2001/XMLSchema#string

Tibor Krisko

http://www.w3.org/2001/XMLSchema#string

Xiaoxin X Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of membrane-type receptor for bile acids (M-BAR)

A G protein-coupled receptor responsive to bile acids

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Alternative activation of macrophages

Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P.

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

The bile acid receptor FXR is a modulator of intestinal innate immunity

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

Obesity induces a phenotypic switch in adipose tissue macrophage polarization

P304

11761-11770

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M112.446575

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

288

http://www.w3.org/2001/XMLSchema#string

P50

Lucy Golden-Mason

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235787853

http://www.w3.org/2001/XMLSchema#string

P698

23460643

http://www.w3.org/2001/XMLSchema#string

P932

3636865

http://www.w3.org/2001/XMLSchema#string